NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

Amphastar Pharmaceuticals logo
$28.25 +0.14 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$28.26 +0.01 (+0.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Advanced

Key Stats

Today's Range
$27.79
▼
$28.70
50-Day Range
$23.62
▼
$29.71
52-Week Range
$16.65
▼
$31.00
Volume
497,439 shs
Average Volume
512,367 shs
Market Capitalization
$1.20 billion
P/E Ratio
12.90
Dividend Yield
N/A
Price Target
$23.33
Consensus Rating
Reduce

Company Overview

Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients.

The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.

Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar serves customers primarily in the United States and also reaches international markets through its operations and commercial relationships.

AI Generated. May Contain Errors.

Amphastar Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

AMPH MarketRank™: 
1.30745939994 of 5 stars

Amphastar Pharmaceuticals scored higher than 26% of companies evaluated by MarketBeat, and ranked 742nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amphastar Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.

  • Downside Risk

    Amphastar Pharmaceuticals has a consensus price target of $23.33, representing about 17.4% downside from its current price of $28.25.

  • Amount of Analyst Coverage

    Amphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Amphastar Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amphastar Pharmaceuticals are expected to decrease by -2.61% in the coming year, from $2.68 to $2.61 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amphastar Pharmaceuticals is 12.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.30.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amphastar Pharmaceuticals is 12.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.47.

  • Price to Earnings Growth Ratio

    Amphastar Pharmaceuticals has a PEG Ratio of 5.25. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amphastar Pharmaceuticals has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.23% of the float of Amphastar Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 11.34, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Amphastar Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving.
  • Dividend Yield

    Amphastar Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amphastar Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Amphastar Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    4 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,232,836.00 in company stock.

  • Percentage Held by Insiders

    29.60% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amphastar Pharmaceuticals' insider trading history.
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMPH Stock News Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Raised to $25.00
See More Headlines

AMPH Stock Analysis - Frequently Asked Questions

Amphastar Pharmaceuticals' stock was trading at $26.78 at the beginning of the year. Since then, AMPH shares have increased by 5.5% and is now trading at $28.25.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its earnings results on Thursday, November, 5th. The company reported $1.14 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.28. The firm earned $207.61 million during the quarter, compared to analyst estimates of $197.52 million. Amphastar Pharmaceuticals had a net margin of 13.27% and a trailing twelve-month return on equity of 15.31%.
Read the conference call transcript
.

Amphastar Pharmaceuticals (AMPH) raised $88 million in an initial public offering on Wednesday, June 25th 2014. The company issued 8,000,000 shares at a price of $10.00-$12.00 per share.

Amphastar Pharmaceuticals' top institutional investors include State Street Corp (3.93%), American Century Companies Inc. (3.72%), Marshall Wace LLP (2.85%) and Goldman Sachs Group Inc. (1.40%). Insiders that own company stock include Mary Z Luo, Rong Zhou, William J Peters, Yakob Liawatidewi, Floyd F Petersen, Richard K Prins and Michael A Zasloff.
View institutional ownership trends
.

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Salesforce (CRM), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AMPH
CIK
1297184
Employees
1,976
Year Founded
1996

Price Target and Rating

High Price Target
$30.00
Low Price Target
$20.00
Potential Upside/Downside
-17.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.19
Trailing P/E Ratio
12.90
Forward P/E Ratio
10.82
P/E Growth
5.25
Net Income
$98.09 million
Net Margins
13.27%
Pretax Margin
17.37%
Return on Equity
15.31%
Return on Assets
7.15%

Debt

Debt-to-Equity Ratio
0.75
Current Ratio
3.32
Quick Ratio
2.36

Sales & Book Value

Annual Sales
$745.79 million
Price / Sales
1.62
Cash Flow
$4.05 per share
Price / Cash Flow
6.98
Book Value
$19.10 per share
Price / Book
1.48

Miscellaneous

Outstanding Shares
42,652,000
Free Float
30,027,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.93

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:AMPH) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners